Anteris Technologies Reports 2024 Financial Results
EAGAN, Minn. and BRISBANE, Australia – Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR), a leading global player in the field of structural heart innovation, recently disclosed its financial outcomes for the year ending December 31, 2024, along with crucial updates on its corporate activities.
2024 Highlights and Recent Developments
This past year has been pivotal for Anteris, marked by substantial achievements and strategic progress. Notably, the Company successfully completed its Initial Public Offering (IPO) on Nasdaq, attracting $88.8 million (AUD $139.3 million) prior to expenses and contributing to its re-domiciliation in the United States.
Pivotal Trial Preparation
Anteris continued to gear up for the DurAVR® Transcatheter Heart Valve’s (THV) upcoming randomized global pivotal study, with a request for Investigational Device Exemption (IDE) on track for submission to the U.S. Food and Drug Administration (FDA) in early 2025.
Expansion of Clinical Experience
With 86 patients treated to date, the Company has collected additional positive clinical findings to bolster its IDE submission. The initial two cases of the DurAVR® THV were executed as part of the European Early Feasibility Study (EU-EFS) at Structural Heart Copenhagen in Denmark, achieving favorable patient outcomes in January 2025.
Increased Brand Awareness
Throughout the year, Anteris amplified awareness of the DurAVR® THV system within the medical community, marked by prominent presentations at significant conferences including New York Valves and the TCT Conference.
Manufacturing Enhancements
The design optimization of the balloon-expandable ComASUR® delivery system has been finalized, alongside scaled manufacturing upgrades in facilities located in Malaga, Australia, and Minneapolis, U.S., preparing for the Pivotal Trial.
Market Position and Financial Overview
As 2024 came to a close, Anteris maintained a robust cash position of $70.5 million (AUD $113.3 million). The financial highlights revealed net sales amounting to $2.7 million and a net loss after taxes totaling $76.0 million, primarily due to research and development expenditures associated with the Pivotal Trial and increased operational costs related to the company's transition to the U.S. market.
Corporate Financing Activities
In a move to enhance liquidity, Anteris entered into a AUD $25 million secured convertible note facility with Obsidian Global Partners, LLC, drawing down AUD $7.5 million, which was fully repaid from the proceeds of the U.S. IPO. The company successfully completed its IPO in December 2024, raising $79.6 million through the sale of 14.8 million shares at $6.00 each, marking its debut on the Nasdaq Global Market.
About Anteris Technologies
Founded in Australia with a significant base in the United States, Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is focused on advancing innovative medical devices aimed at restoring heart health. The flagship product, the DurAVR® THV, was developed in collaboration with renowned interventional cardiologists and aims to provide a minimally invasive solution for aortic stenosis. Utilizing the company’s proprietary ADAPT® tissue technology, the DurAVR® serves as a groundbreaking treatment option for patients suffering from this life-threatening condition.
Frequently Asked Questions
What were Anteris Technologies' key financial results for 2024?
In 2024, Anteris reported net sales of $2.7 million and a net loss after tax of $76 million.
What is the DurAVR® THV system?
The DurAVR® THV system is a cutting-edge device designed to treat aortic stenosis, featuring innovative ADAPT® tissue technology.
How much did the U.S. IPO raise for Anteris?
The initial public offering raised $79.6 million, which facilitated the company's financial positioning post-re-domiciliation.
What are the plans for the Pivotal Trial?
Anteris is preparing to submit an IDE application to the FDA in early 2025 to commence the Pivotal Trial for its DurAVR® THV system.
Where can I find more information about Anteris?
Further details can be obtained via their official website at www.anteristech.com or contact their Investor Relations team.
